Implant, Hormonal IUD Effective Beyond FDA-Approved Duration

Share this content:
Implant, Hormonal IUD Effective Beyond FDA-Approved Duration
Implant, Hormonal IUD Effective Beyond FDA-Approved Duration

(HealthDay News) -- The contraceptive implant and the 52-mg hormonal intrauterine device (IUD) seem to be effective beyond the U.S. Food and Drug Administration-approved duration, according to a study published online Feb. 4 in Obstetrics & Gynecology.

Colleen McNicholas, D.O., from the Washington University School of Medicine in St. Louis, and colleagues examined the effectiveness of the contraceptive implant and 52-mg hormonal IUD in women using the methods beyond the FDA-approved duration of three and five years, respectively. Data were included for 237 implant users and 263 levonorgestrel IUD users who were willing to continue using their implant or IUD beyond the FDA-approved duration.

The researchers found that among the implant users, 123 used the etonogestrel implant for four years and 34 used it for five years. There were no pregnancies documented among the implant users, for a failure rate of 0 per 100 women-years. Among 263 levonorgestrel IUD users, there was one pregnancy confirmed, for a failure rate of 0.51 per 100 women-years. The median etonogestrel level at three and four years of use was 188.8 pg/mL and 177.0 pg/mL, respectively, among implant users with serum etonogestrel results. At three and four years, etonogestrel levels did not differ by body mass index (P = 0.79 and 0.47, respectively).

"Preliminary findings indicate the contraceptive implant and 52-mg hormonal IUD continue to be highly effective for an additional year beyond the FDA-approved three and five years," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Dupilumab Reduces Rate of Severe Asthma Exacerbations

Dupilumab Reduces Rate of Severe Asthma Exacerbations

And, add-on dupilumab reduces glucocorticoid dose in patients with glucocorticoid-treated asthma

Better Social Support Network Protects Black Men Against HIV

Better Social Support Network Protects Black Men Against ...

Social networks of black men who have sex with men influence HIV risk behavior

Recommendations Developed for Managing Postpartum Pain

Recommendations Developed for Managing Postpartum Pain

Impact of medications on mother-infant dyad should be considered, as many women breastfeed

is free, fast, and customized just for you!

Already a member?

Sign In Now »